Second cancer incidence in CLL patients receiving BTK inhibitors

Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resulting in partial restoration of immune function. The incidence of and risk factors for SPM...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2020-12, Vol.34 (12), p.3197-3205
Hauptverfasser:	Bond, David A., Huang, Ying, Fisher, James L., Ruppert, Amy S., Owen, Dwight H., Bertino, Erin M., Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Jaglowski, Samantha M., Maddocks, Kami J., Byrd, John C., Woyach, Jennifer A.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/602 631/67/1990/283/1895 631/67/2195 Adult Aged Aged, 80 and over Benzamides - adverse effects Benzamides - therapeutic use Cancer Cancer Research CD8 antigen Chronic lymphocytic leukemia Complications and side effects Critical Care Medicine Drug therapy Enzyme inhibitors Female Genetic aspects Health risks Hematology Humans Immune response Incidence Intensive Internal Medicine Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - metabolism Lymphatic leukemia Male Medicine Medicine & Public Health Melanoma Middle Aged Neoplasms, Second Primary - chemically induced Neoplasms, Second Primary - etiology Neoplasms, Second Primary - metabolism Oncology Oncology, Experimental Patient outcomes Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - metabolism Pyrazines - adverse effects Pyrazines - therapeutic use Retrospective Studies Risk analysis Risk Factors Second primary cancer Skin cancer Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!